Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice

Ai-Qing Zheng, Xian-Rang Song, Jin-Ming Yu, Ling Wei, Xing-Wu Wang

AIM: To evaluate whether intratumoral injection of liposome-endostatin complexes could enhance the antitumor efficacy of radiation therapy in human liver carcinoma (BEL7402) model.

METHODS: Recombinant plasmid pcDNA3.End was transfected into human liver carcinoma cell line (BEL7402) with lipofectamine to produce conditioned medium. Then BEL7402 cells and human umbilical vein endothelial cells (HUVECs) were treated with the conditioned medium. Cell cycle and apoptosis were analyzed by flow cytometer and endothelial cell proliferation rates were determined by MTT assay. The antitumor efficacy of endostatin gene combined with ionizing radiation in mouse xenograft liver tumor was observed.

RESULTS: Endostatin significantly suppressed the S phase fraction and increased the apoptotic index in HUVECs. In contrast, endostatin treatment had no effect on BEL7402 cell apoptosis (2.1±0.3% vs 8.9±1.3%, t = 8.83, P = 0.009<0.01) or cell cycle distribution (17.2±2.3% vs 9.8±1.2%, t = 4.94, P = 0.016<0.05). The MTT assay showed that endostatin significantly inhibited the proliferation of HUVECs by 46.4%. The combination of local endostatin gene therapy with radiation therapy significantly inhibited the growth of human liver carcinoma BEL7402 xenografts, the inhibition rate of tumor size was 69.8% on d 28 compared to the untreated group. The tumor volume in the pcDNA3.End combined with radiation therapy group (249±83 mm³) was significantly different from that in the untreated group (823±148 mm³, t = 5.86, P = 0.009<0.01) or in the pcDNA3 group (717±94 mm³, t = 6.46, P = 0.003<0.01). Endostatin or the radiation alone also inhibited the growth of liver tumor in vivo, but their inhibition effects were weaker than those of endostatin combined with radiation, the inhibition rates on d 28 were 44.7% and 40.1%, respectively.

CONCLUSION: Endostatin not only significantly suppresses tumor growth but also enhances the antitumor efficacy of radiation therapy in human carcinoma xenograft.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Endostatin; Human liver carcinoma; Radiotherapy; Gene therapy

Zheng AQ, Song XR, Yu JM, Wei L, Wang XW. Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice. World J Gastroenterol 2005; 11(28): 4439-4442

http://www.wjgnet.com/1007-9327/11/4439.asp

INTRODUCTION

Tumors are dependent on angiogenesis for sustained growth[1]. Endostatin, an endogenous antiangiogenic agent, is a M, 20 000 COOH-terminal fragment of collagen XVIII. It is a potent inhibitor of angiogenesis in vitro, and has significant antitumor effects in a variety of preclinical tumor models[2-3]. Endostatin specifically inhibits endothelial cell proliferation without direct effects on tumor cell or non-neoplastic cell growth[4-7], whose overexpression can lead to primary tumor regression and growth inhibition[8].

Most therapeutic investigations of endostatin utilized the purified protein, but the protein purification process is difficult and may denature endostatin. For maintaining therapeutically effective serum levels the protein must be repeatedly used because it has a short half-life in vivo. One possible approach to overcome this problem may be the utilization of gene therapy strategy. Studies using viral vectors to deliver endostatin gene have demonstrated its efficacy in treatment of mouse tumor models[9-11].

Although antiangiogenic therapies have shown significant antitumor effects in preclinical investigations, angiogenesis inhibitors cannot achieve tumor cures on their own. Antiangiogenic strategies in combination with conventional anticancer approaches may achieve better results. The involvement of antiangiogenic agents during the course of radiotherapy have been shown to produce significant therapeutic effects[12-15].

In this study, we investigated whether intratumoral injection of liposome-endostatin complexes could enhance the treatment efficacy of ionizing radiation in a human liver carcinoma (BEL7402) model.

ENDOSTATIN: An endogenous anti-angiogenic factor

Endostatin is a 20 000 dalton COOH-terminal fragment of collagen XVIII. It has been shown to inhibit angiogenesis and tumor growth in preclinical investigations. However, its clinical application has been limited due to issues such as protein instability and dose-related toxicity.

METHODS: Recombinant plasmid pcDNA3.End was transfected into human liver carcinoma cell line (BEL7402) with lipofectamine to produce conditioned medium. Then BEL7402 cells and human umbilical vein endothelial cells (HUVECs) were treated with the conditioned medium. Cell cycle and apoptosis were analyzed by flow cytometer and endothelial cell proliferation rates were determined by MTT assay. The antitumor efficacy of endostatin gene combined with ionizing radiation in mouse xenograft liver tumor was observed.

RESULTS: Endostatin significantly suppressed the S phase fraction and increased the apoptotic index in HUVECs. In contrast, endostatin treatment had no effect on BEL7402 cell apoptosis (2.1±0.3% vs 8.9±1.3%, t = 8.83, P = 0.009<0.01) or cell cycle distribution (17.2±2.3% vs 9.8±1.2%, t = 4.94, P = 0.016<0.05). The MTT assay showed that endostatin significantly inhibited the proliferation of HUVECs by 46.4%. The combination of local endostatin gene therapy with radiation therapy significantly inhibited the growth of human liver carcinoma BEL7402 xenografts, the inhibition rate of tumor size was 69.8% on d 28 compared to the untreated group. The tumor volume in the pcDNA3.End combined with radiation therapy group (249±83 mm³) was significantly different from that in the untreated group (823±148 mm³, t = 5.86, P = 0.009<0.01) or in the pcDNA3 group (717±94 mm³, t = 6.46, P = 0.003<0.01). Endostatin or the radiation alone also inhibited the growth of liver tumor in vivo, but their inhibition effects were weaker than those of endostatin combined with radiation, the inhibition rates on d 28 were 44.7% and 40.1%, respectively.

CONCLUSION: Endostatin not only significantly suppresses tumor growth but also enhances the antitumor efficacy of radiation therapy in human carcinoma xenograft.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Endostatin; Human liver carcinoma; Radiotherapy; Gene therapy

Zheng AQ, Song XR, Yu JM, Wei L, Wang XW. Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice. World J Gastroenterol 2005; 11(28): 4439-4442

http://www.wjgnet.com/1007-9327/11/4439.asp
MATERIALS AND METHODS

Plasmid and cell lines
The plasmid pcDNA3.End containing a synthetic rat insulin leader sequence and the full-length mouse endostatin cDNA was kindly provided by Dr. Wang Jianli (Shandong Medical University, Jinan, China). The synthetic rat insulin leader was cloned in front of the endostatin gene. Human liver carcinoma cell line BEL7402 and human umbilical vein endothelial cell line (HUVEC) were kept in our laboratory. HUVECs and BEL7402 cells were maintained in DMEM (Gibco) containing 10% FBS.

In vitro transfection and production of conditioned endostatin medium
BEL7402 cells were grown in 6-well plates at the density of 2×10^5 cells/well to 50-80% confluence, then transfected with 10 µL of lipofectamine (Invitrogen) mixed with 4 µg of plasmid (pcDNA3.End or pcDNA3) as described by the Invitrogen protocol. After 24 h transfection, the cells were extensively rinsed with PBS and incubated in serum-free DMEM for another 24 h. The conditioned media were collected, centrifuged and cell debris was cleared off. Endostatin in the culture media was measured with a murine endostatin enzyme immunoassay kit (Chemicon Inc.). The conditioned media were concentrated 20-fold with Amicon membranes (Amicon Inc.), and endostatin protein levels were determined by immunoassay before being stored at -80 ºC for further use.

Cell cycle assay
BEL7402 cells and HUVECs were plated in 6-well plates at the density of 2×10^4 cells/well and allowed to attach overnight. The cells were treated with conditioned medium containing certain concentration of endostatin and 10% FBS after removal of the medium. Forty-eight hours later, the cells were trypsinized, counted and fixed in 50% ethanol overnight, then treated with PBS (containing 1 g/L RNase) for 30 min. Samples were washed with PBS twice and resuspended in PBS at a concentration of 1×10^6 cells/mL. The cells were stained with PI in darkness for 30 min and cell cycle distribution was analyzed with a flow cytometer (Becton-Dickinson FACS Calibur).

Apoptosis assay
BEL7402 cells and HUVECs were cultured in 6-well plates at the density of 2×10^5 cells/well and incubated for 24 h. The medium was replaced with 2 mL of conditioned medium containing certain concentration of endostatin and 10% FBS. After being incubated for 48 h, the cells were trypsinized, counted, washed twice with cold PBS and then resuspended in 1× binding buffer at a concentration of 1×10^6 cells/mL. Five microliters of annexin V-FITC and five microliters of PI were added. The cells were gently vortexed and incubated for 15 min at RT in the dark, and then 400 µL of 1× binding buffer was added. Apoptosis was analyzed with a flow cytometer.

Endothelial cell proliferation assay
HUVECs were incubated in 96-well plates at the density of 10^4 cells/well and allowed to attach overnight. The medium was then replaced with 20 µL of conditioned medium and incubated for 30 min. Eighty microliters of DMEM containing with 10% FBS and 1 µg/L bFGF (Sigma) were then added. After the cells were incubated for 48 h, 20 µL MTT solution (5 g/L) was added. Then, 4 h later, 100 µL 100 g/L SDS was added. After being vortexed gently for 10 min, the number of cells was quantified by colorimetric MTT assay.

RESULTS

In vitro endostatin quantification
Unconditioned media (100 µL) collected from BEL7402 cells transfected with pcDNA3.End and pcDNA3 were measured with a murine endostatin enzyme immunoassay kit. The experiment showed that BEL7402 cells transfected with pcDNA3.End efficiently secreted endostatin protein into the culture media. Endostatin levels were 486.2±56.5 mg/L in conditioned media from BEL7402 cells transfected with pcDNA3.End, and 6.8±2.6 mg/L in conditioned media from BEL7402 cells transfected with pcDNA3. There were significant differences in endostatin levels between the two groups (t = 14.68, P = 0.005<0.01, Figure 1).

Endostatin-affected HUVEC cell cycle and apoptosis
After being treated with conditioned medium, compared to conditioned medium from BEL7402 cells transfected with pcDNA3, conditioned medium from BEL7402 cells transfected with pcDNA3.End significantly suppressed the S phase fraction (17.2±2.3% vs 9.8±1.2%, t = 4.94, P = 0.016<0.05) and increased the apoptotic index (2.1±0.3% vs 9.8±1.2%, t = 4.94, P = 0.016<0.05). HUVECs treated with the two-conditioned media respectively,
there were no differences in BEL7402 cell apoptosis or cell cycle distribution, suggesting that endostatin treatment had no effect on BEL7402 tumor cell apoptosis or cell cycle distribution.

Endostatin-inhibited endothelial cell proliferation

After 24 h incubation with conditioned media, endostatin-inhibited HUVECs proliferation by 46.4±9.7%, while the conditioned media derived from cultures of BEL7402 cells transfected with pcDNA3 control vector did not affect endothelial cell proliferation, the inhibition rate was 8.7±0.5% ($t = 6.72$, $P = 0.02<0.05$, Figure 2).

Endostatin gene therapy combined with radiation-inhibited tumor growth in nude mice

As shown in Figure 3, tumors treated with Lip-pcDNA3.End combined with radiation group grew very slowly in nude mice, the inhibition rate of tumor size was 69.8% on d 28 compared to untreated group. The tumor volume of the pcDNA3.End group ($492±97$ mm$^3$, $t = 5.86$, $P = 0.009<0.01$) or the radiation group ($455±124$ mm$^3$, $t = 6.46$, $P = 0.003<0.01$). Tumors of the pcDNA3.End group and radiation group also grew slower than those of the untreated group or the pcDNA3 group, but the inhibitory effects on tumor growth were slightly weaker than those of the pcDNA3.End combined with radiation group, the inhibitory rates on d 28 were 44.7% and 40.1%, respectively. The tumor volume of the pcDNA3.End group ($492±97$ mm$^3$) or the radiation group ($455±124$ mm$^3$) was significantly different from that of the untreated group (the pcDNA3.End group, $t = 3.14$, $P = 0.039<0.05$ and the radiation group, $t = 3.30$, $P = 0.03<0.05$ or the pcDNA3 group (the pcDNA3.End group, $t = 2.89$, $P = 0.045<0.05$ and the radiation group, $t = 2.92$, $P = 0.047<0.05$).

DISCUSSION

Radiotherapy is one of the most important treatment modalities for solid tumors. Today, 45-50% of all cancer patients can be cured, and nearly 70% of those who are cured have received radiation either alone or in combination with other modalities, but a large number of patients have no response to radiotherapy treated with curative intent ultimately fail, not only because of metastasis of the disease, but also because of relapse at the local treatment site. One reason responsible for radiotherapy failure may be the tumor vasculature. Numerous studies have shown that tumor cells stop growing when the diameter of tumor exceeds 1-2 mm if new blood vessels supplying the tumor fail to generate. Hence, the combined radiotherapy with antiangiogenic agents has aroused great concerns.

Angiogenesis is a complex process with multiple, sequential, and interdependent steps. Tumor cells promote new vessel formation by releasing endothelial cell growth factors that support endothelial cell proliferation, migration, and survival. Tumor angiogenesis is the consequence of enhanced expression of proangiogenic factors relative to antiangiogenic factors in the tumor microenvironment.

The combination of radiation treatment with endostatin may improve radiotherapy outcome by enhancing antitumor efficacy, reducing the total radiation dose, improving local tumor control rate, alleviating radiation damage. These considerations, along with the extensive clinical use of radiotherapy, make thorough investigation of strategies combining conventional treatment modality with endostatin. It was reported that combined endostatin gene therapy with radiotherapy can improve tumor response.

We chose liposome to transfect BEL7402 cells with endostatin gene due to its high transfection efficiency. In
our pre-experiment, we chose lipofectamine to transfect BEL7402 cells with pcDNA3.GFP, the transfection rate was 73.5%. ELISA analysis of conditioned media from BEL7402 cells transfected with pcDNA3.End showed that the level of endostatin protein was 486.2±56.5 mg/L, suggesting that BEL7402 cells transfected with pcDNA3.End plasmids secrete endostatin proteins into the culture media. The conditioned medium significantly suppressed the S phase fraction and increased the apoptotic index in HUVECs. However, it had no effect on BEL7402 cell apoptosis or cell cycle distribution. In vivo, endostatin significantly enhanced the treatment efficacy of ionizing radiation. The antitumor inhibition rate of combined endostatin gene therapy with radiation in BEL7402 human liver tumor model was 69.8%, which was significantly different from the untreated group ($t = 5.86, P = 0.009<0.01$) or the empty vector group ($t = 6.46, P = 0.003<0.01$) on d 28. Tumors of the radiation group and the pcDNA3.End group grew slower than those of the untreated group or the pcDNA3 group. These results indicate that intratumoral injection of liposome-endostatin complex significantly enhances the antitumor efficacy of radiation therapy.

In summary, gene therapy can deliver antiangiogenic polypeptide endostatin. Cationic liposomes transfected to endostatin gene can not only suppress endothelial cell proliferation, but also enhance the treatment efficacy of ionizing radiation.

REFERENCES

1 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31
2 Perletti G, Concari P, Giardini R, Marras E, Piccinini F, Folkman J, Chen L. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 2000; 60: 1793-1796
3 Chen OR, Kumar D, Stass SA, Misson AJ. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999; 59: 3308-3312
4 Du Z, Hou S. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol 2003; 170: 2000-2003
5 Wang X, Liu F, Li X, Li JS, Xu GX. Anti-tumor effect of human endostatin mediated by retroviral gene transfer in nude mice. Chin Med J 2002; 115: 1664-1669
6 Boehle AS, Kurdow R, Schulze M, Kliche U, Sipos B, Soondrum K, Ebrahimnejad A, Doehrmann P, Kalthoff H, Henne-Bruns D, Neuemaier M. Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer 2001; 94: 420-428
7 Felbor U, Dreier L, Bryant RAR, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen X VIII. EMBO J 2000; 19: 1187-1194
8 Herbst RS, Lee AT, Tran HT, Abbuzzese JL. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 2001; 3: 131-140
9 Sauter BV, Martinet O, Zhang WJ, Mandeli J, Wou SLC. Angenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 2000; 97: 4802-4807
10 Ding XQ, Chen Y, Li L, Liu RY, Huang JL, Lai K, Wu XJ, Ke ML, Huang WL. Inhibition of tongue cancer development in nude mice transfected with adenovirus carrying human endostatin gene. Aizheng 2003; 22: 1152-1157
11 Chen W, Fu J, Liu Q, Ruan C, Xiao SD. Retroviral endostatin gene transfer inhibits human colon cancer cell growth in vivo. Chin Med J 2003; 116: 1582-1584
12 Gorski DH, Maceteri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kute DW, Weichselbaum RR. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998; 58: 5686-5689
13 Wachberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with angiostogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9: 1957-1971
14 Griscelli F, Li H, Cheong C, Opolon P, Bennaceur-Griscelli A, Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci USA 2000; 97: 6698-6703
15 Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427-433
16 Hahnelfeld P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999; 59: 4770-4775
17 Roefstad EK, Henriksen K, Galappathi K, Mathiesen B. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res 2003; 63: 4055-4061
18 Lund EJ, Bastholm L, Kristjansen PEG. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 2000; 6: 971-978
19 Siemann DW, Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 2003; 13: 53-61
20 Herbst RS, O'Reilly MS. The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. Semin Oncol 2003; 30 (4 Suppl 9): 113-123
21 Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiat Oncol 2003; 66: 1-9
22 Greenberger JS. Antitumor interaction of short course endostatin and ionizing radiation. Cancer J 2000; 6: 279-281